Kerrisdale Advisers’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Kerrisdale Advisers’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-36,753	Closed	-$452K	–	37
2019 Q2	$452K	Hold	36,753	–	–	0.16%	29
2019 Q1	$459K	Hold	36,753	–	–	0.09%	32
2018 Q4	$416K	Sell	36,753 -392	-1%	-$6.15K	0.26%	22
2018 Q3	$695K	Hold	37,145	–	–	0.68%	14
2018 Q2	$960K	Buy	37,145 +5,345	+17%	+$139K	0.4%	13
2018 Q1	$713K	Buy	+31,800	New	+$776K	0.5%	16

Other funds holding FLXN

MVP

Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Kerrisdale Advisers's FLXN Position: Q3 2019 in Review

Kerrisdale Advisers sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2019, closing a stake of 36,753 shares — an estimated $452K sold.

Kerrisdale Advisers first reported a position in FLXN in Q1 2018 and held it in 6 quarters. The position peaked at $960K in Q2 2018. 126 funds tracked by Wall St. Rank hold FLXN as of Q3 2019.

Kerrisdale Advisers reported no remaining Flexion Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Kerrisdale Advisers sold 36,753 Flexion Therapeutics, Inc. shares in Q3 2019, an estimated $452K.
Kerrisdale Advisers first reported a position in Flexion Therapeutics, Inc. in Q1 2018 and held it in 6 quarters.
Kerrisdale Advisers's Flexion Therapeutics, Inc. position peaked at $960K in Q2 2018.
126 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2019.

Based on Kerrisdale Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.